davemessina

Hi Jake,

While we have no immediate plans to hire out west, we are changing rapidly and that certainly could change in the future.

We'll be offering our test to patients through doctors and hospitals — imagine going for your annual checkup, and our test is ordered along with all of the other routine blood tests. This is the fastest route for us to be able to get our test onto the market and making a impact on people's lives.

I am not an expert in gene therapy, but I think getting the transcription or translation machinery to read the "good" copy instead of the stop codon would be the challenge there.

circRNA have so much value already as a way to diagnose disease — we're excited about just that powerful capability! Our understanding of circRNAs is just beginning, and it'll be interesting to see what other applications for them are invented.

Hi everyone! Dave Messina from Cofactor Genomics here. I'd be happy to answer any questions you might have.

Yes.

Thanks for your comments, and yes, you've got it exactly.

In cancer, both DNA and RNA can be effective diagnostics, and there's been a lot of great work on the DNA side in cancer.

In essentially all other diseases, though, there are changes in RNA but not in DNA.

It's the fastest way for us to get this powerful diagnosis technology on the market and helping people.

We believe that our RNA test can become a routine part of a doctor's visit, both as an early indicator of disease and — if there is disease — as a means to monitor the effectiveness of treatment.